On December 8, Kevin Mahn of Hennion & Walsh appeared on CNBC’s ‘Closing Bell Overtime’ to discuss the potential for another bullish year, but with more volatility. Mahn noted the possibility of a hawkish cut from the Fed coming up on Wednesday, which he believes could bode well for the markets. He supported this with historical data and stated that since 1950, the Fed has cut interest rates on 23 different occasions when the S&P 500 was within 2% of its all-time high, as it is currently. In all 23 of those instances, the market moved higher over the next 12 months by an average of just under 14%. While acknowledging that this time could be different, Mahn expressed his view that the bull market will continue its run and notch its fourth consecutive year in 2026, though he expects many more bumps in the road along the way and much more short-term volatility than 2025.
Mahn also confirmed that if the Fed cuts interest rates this week, the Fed Fund’s target rate would move into a range of 3.5% to 3.75%. He noted that the Fed’s neutral rate is 3% (unless updated this week), which would leave only 50 basis points (or two 25 basis point cuts) remaining to reach neutral. He does not expect any cuts in Q1, noting that Q1 will include Chair Powell’s last two live FOMC meetings before he’s replaced as chair. Mahn suggested that they may only get one rate cut in 2026 and one in 2027. He then identified the big outstanding vote as the change in Fed Chair, which he noted could change everything. He expects the new Fed Chair to be more dovish, potentially resulting in a single 50 basis point cut when the new Chair takes over in the spring.
That being said, we’re here with a list of the 20 stocks that will double in 2026.
Our Methodology
We sifted through financial media reports and stock screeners to compile a list of the top stocks that will double in 2026 (with an upside potential between 100% and 200%). We then selected the 20 stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q3 2025.
Note: All data was sourced on December 10.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
20 Stocks That Will Double in 2026
20. Bitfarms Ltd. (NASDAQ:BITF)
Average Upside Potential as of December 10: 104.08%
Number of Hedge Fund Holders: 25
Bitfarms Ltd. (NASDAQ:BITF) is one of the stocks that will double in 2026. On November 14, Alliance Global analyst Brian Kinstlinger raised the firm’s price target on Bitfarms to $6 from $2.50 and kept a Buy rating on the shares. This sentiment followed the company’s Q3 2025 earnings report. Kinstlinger believes that Bitfarms’ stock deserves a much higher multiple because the company is actively mitigating risks associated with timing, capital requirements, and future tenant demand. Bitfarms plans to transition most of its energy capacity to facilities dedicated to AI to generate long-term recurring revenue and yield very high margins, which could justify a higher valuation for the firm.
In its Q3 2025 earnings report, Bitfarms highlighted significant progress in transitioning from Bitcoin mining to becoming a leading North American HPC and AI infrastructure provider. However, this transition requires significant capital expenditure and operational changes, leading to inherent execution risks. A major uncertainty is the exact timeline for securing additional power capacity at key sites, specifically Panther Creek and Scrubgrass, which could delay project milestones. In the short term, winding down Bitcoin mining operations, starting with the sale of the Paso Pace facility (about 20% of their hash rate), will affect immediate cash flow until the HPC and AI projects become fully operational.
The company was able to make a total revenue of $83.66 million, which was an 86.52% increase as compared to the year-ago period, although this number missed Street expectations by $998.78K. However, Bitfarms generated a quarterly loss of $0.15 per share in Q3.
Bitfarms Ltd. (NASDAQ:BITF) operates integrated bitcoin data centers in Canada, the US, Paraguay, and Argentina. It primarily owns and operates data centers housing computers and sells computational power in multiple jurisdictions.
19. Solid Biosciences Inc. (NASDAQ:SLDB)
Average Upside Potential as of December 10: 155.10%
Number of Hedge Fund Holders: 25
Solid Biosciences Inc. (NASDAQ:SLDB) is one of the stocks that will double in 2026. On December 4, Needham analyst Gil Blum initiated coverage of Solid Biosciences with a Buy rating and $16 price target. Blum noted that the recent deaths of two non-ambulatory Duchenne muscular dystrophy patients who received Sarepta’s drug, Elevidys, raise concerns about the treatment’s benefit-risk profile. This safety issue may create a significant opportunity for competing gene therapies, specifically citing Solid Biosciences’ SGT-003. SGT-003 is intentionally designed to minimize liver toxicity while maintaining efficacy, and early trial results for SGT-003 have already shown robust microdystrophin expression.
In its Q3 2025 earnings report, Solid Biosciences disclosed that the company ended the quarter with $236.1 million in cash, cash equivalents, and available-for-sale securities, compared to $148.9 million as of December 31, 2024. This cash position is projected to fund the company’s operational runway into H1 2027. The net loss for Q3 was $45.8 million, up from $32.7 million in Q3 2024, primarily due to an increase in R&D expenses, which rose to $38.9 million from $27.3 million in Q3 2024, mainly driven by increased costs for the SGT-003 program.
Solid Biosciences’ SGT-003 Duchenne gene therapy trial (INSPIRE DUCHENNE) showed strong efficacy as of September 29, with all 10 participants evaluated at Day 90 achieving a mean microdystrophin expression of 58% and key DAPC restoration. The therapy was generally well tolerated with a steroid-only regimen, showing favorable cardiac safety signals and no DILI. The company has dosed 23 participants as of October 31, and plans to meet with the FDA in H1 2026 to discuss accelerated approval pathways after initiating the Phase 3 IMPACT DUCHENNE trial. The pipeline is also advancing, with new Phase 1b trials for FA (SGT-212) and CPVT (SGT-501) starting in Q4 2025.
Solid Biosciences Inc. (NASDAQ:SLDB) develops therapies for neuromuscular and cardiac diseases in the US. In addition, the company develops platform technologies, including capsid libraries, genetic regulators, immunomodulation technologies, manufacturing purity, and dual gene expression.
